As the US National Cancer Institute (NCI) switches to using patient-derived tumour xenografts in mice for drug screening (see Nature 530, 391; 2016), we warn researchers on behalf of the International Cell Line Authentication Committee (go.nature.com/kphqtx) that xenografts potentially have the same cross-contamination and misidentification problems as cultured cell lines.
For example, at least 4 of the 60 human-cancer cell lines on NCI's panel are affected, as are several NCI-derived lines that were established before contamination testing became widely available (see go.nature.com/csodfc).
Lack of testing or bad practice can undermine the reliability of patient-derived xenografts. Cell cultures from these call for extra quality-control measures, such as screening for cross-species DNA contamination (J. Camps et al. Leuk. Res. 30, 923–934; 2006).
The US National Institutes of Health now requires the authentication of key biological resources, but guidelines and defined protocols are still needed for rigorous characterization of patient-derived xenografts. It will be essential to deposit reference information for cell-based models in public databases, including details of donor DNA profile, host species and strain, testing outcome for host DNA, and methodologies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nardone, R., MacLeod, R. & Capes-Davis, A. Authenticate new xenograft models. Nature 532, 313 (2016). https://doi.org/10.1038/532313a
Published:
Issue Date:
DOI: https://doi.org/10.1038/532313a